Q1 FY27 results: consolidated revenue up 26% YoY; new CFO from Aug 24

Revenue Growth 20pctResults View source PDF Explain this filing

SURAKSHA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+14.7%Reaction day

₹270.00

prior close

₹280.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+14.6% vs market

Healthcare Service Provider peers, median of 26sector+0.3%+14.4% vs sector

On the reaction day the stock moved 14.6 pts more than Nifty Microcap 250 and 14.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

+3.9

15m

+5.7

30m

+6.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+14.7+0.2+14.6+0.3+14.4

Next day

+13.3+0.2+13.1-2.1+15.4

+15.4+0.4+15.1-0.8+16.2

+17.4+0.7+16.7-1.8+19.2

+14.3+0.1+14.2-3.2+17.6

+13.2+0.7+12.6-1.5+14.7

+19.2+1.2+18.0-0.7+19.9

15d

+24.8+0.7+24.1-1.0+25.9

+20.9-1.2+22.1-0.9+21.9

+18.0-1.1+19.1-5.7+23.7

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suraksha Diagnostic reported Q1 FY27 (ended June 30, 2026) results. Standalone revenue rose about 7% YoY to around Rs 84.09 crore; standalone PAT fell about 11% to Rs 12.58 crore. Consolidated revenue grew about 26% YoY to around Rs 111.57 crore; consolidated PAT grew about 14% to Rs 11.15 crore. Standalone EPS was Rs 2.42. Board appointed Mr Dinesh Gupta as CFO effective Aug 24. Record date for FY26 dividend fixed at Sept 15; AGM on Sept 22.

Likely market impact

Mixed Q1: consolidated revenue strong at 26% growth but standalone PAT dipped about 11%. Subsidiary arbitration pending. Dividend and new CFO in focus.